NCT07082595Recruiting
Personalized Stimulation Loop for Neurorehabilitation in Parkinson: a Proof-of-principle Study
Source: ClinicalTrials.gov · Last updated 24 Jul 2025 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
Parkinson's disease (PD) is a neurodegenerative disease that affects about 1% of the elderly population and accounts for substantial disability and health care costs. Disability is largely driven by mobility deficits caused by impaired gait. Effective treatments are available to restore lower limb function and improve gait, but response to treatment varies greatly from patient to patient and often shows only small effect sizes. Addressing this heterogeneity requires personalization, a concept referred to precision neurorehabilitation. StimuLOOP.PD-Sleep intends to foster structured and reproducible methods for precision neurorehabilitation of gait in PD. The investigators will conduct a proof-of-concept study to investigate a sleep intervention tailored to the individual patient in the context of motor rehabilitation. • Targeted auditory stimulation during sleep (TASS): The investigators aim to reactive rehabilitation-related memories through presentation of auditory stimuli during sleep with the goal of promoting motor memory consolidation into stable motor commands. The investigators will leverage TASS to enhance consolidation of the movement patterns that are learned during rehabilitation. The investigators expect that this intervention will lead to greater gains in functional walking ability and balance. Beyond demonstrating a proof-of-concept for novel methods of applying TASS stimulation in the context of neurorehabilitation, positive results of this project may have implications for neurorehabilitation treatment in general by providing first insights into the benefits and interplay of TASS with a rehabilitation.
- Status (registry)
- Recruiting
- Study type
- Interventional
- Enrollment
- 40 (estimated)
- First submitted
- 20 Jun 2025
- Start date
- 7 Jul 2025
- Primary completion date
- 31 Mar 2028
- Lead sponsor
- University of Zurich
- Diseases
- Parkinson disease
- NCT number
- NCT07082595
What you commit to
- Study type: Interventional
- Planned participants: 40
- From 7 Jul 2025 to the primary completion date, 31 Mar 2028
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Patients taking benzodiazepines or Z-drugs that have a significant effect on sleep EEG
- Recent DBS implant (≤ 6 months)
Other illness
- Cognitive impairment, Montreal Cognitive Assessment (MoCa) \< 20
- Other neurological or medical condition that caused sustained clinically relevant gait and/or postural stability deficits
- History of a physical or neurological condition that interferes with study procedures
- Skin disorders/problems/allergies in face/ear area that could worsen with electrode application (e.g. nickel allergy)
Other
- Social and/or personal circumstances that interfere with the ability to return for assessments
- Inability to perform outcome assessments without walking aid
Who the study is looking for
- Idiopathic Parkinson's disease with gait and postural stability deficits
- ≥18 years of age
- UPDRS III gait scores 1-3
- UPDRS III postural instability scores 1-3
- Prescribed rehabilitation therapy
- Informed consent as documented by signature
- Adjustments in dopaminergic medication and DBS stimulation to improve
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| University of Zurich Coordinator of this site? Confirm its status | Zurich | Switzerland | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.